氨酸抑制颗粒状细胞铁灭,以维持卵巢功能
Hao-Cheng Gu1,2,3, You-Qiong Zhuo2,4, Ling-Fang Wang2
1School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
Nature communications
|January 21, 2026
概括
食血清补充剂通过防止花质细胞铁致死,防止化疗诱导的卵巢损伤. 这一发现揭示了早期卵巢衰竭的共同机制,并表明血清素是卵巢健康的关键因素.
科学领域:
- 生殖生物学 生殖生物学
- 在瘤学瘤学.
- 代谢医学是一种代谢医学.
背景情况:
- 环胺 (CTX) 是一种重要的乳腺癌治疗方法,经常导致过早的卵巢缺陷 (POI).
- CTX诱导的POI与增加SLC1A4的表达有关,促进卵巢颗粒细胞 (GCs) 中的血清流出.
- 血清血清蛋白水平降低与接受CTX治疗的患者和生活方式引起的压力女性的卵巢功能下降相关.
研究的目的:
- 研究血清素在化疗引起的和异常性POI中的作用.
- 探索食血清补充剂在预防POI的治疗潜力.
- 阐明基因细胞中赛林的保护作用背后的分子机制.
主要方法:
- 对接受CTX治疗的乳腺癌患者和生活方式引起的卵巢压力的妇女的血清血清蛋白水平的分析.
- 向暴露于CTX的小鼠提供食血清补充剂.
- 在治疗和对照组中评估卵巢功能,组织学和分子标记 (SLC1A4,S1P,Nrf2,HO-1,ferroptosis).
- 对CTX在补充血清素的小鼠中的抗癌疗效的评估.
主要成果:
- 食血清补充剂有效地保护小鼠免受CTX诱导的POI,而不会影响抗癌作用.
- 发现高血清素水平促进了斯芬戈-1-酸盐 (S1P) 的合成.
- 氨酸的作用抑制了Nrf2核转位和随后的HO-1表达,从而抑制了GCs中的铁亡.
结论:
- 化疗诱导的和异常性POI共享了涉及氨酸代谢的共同潜在机制.
- 氨酸是维持卵巢功能和预防GC铁亡的关键因素.
- 食血清补充剂是减轻癌症患者和潜在的其他人群中POI的有希望的策略.
相关概念视频
00:46Feedback Inhibition
56.9K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
56.9K
01:19Design Example: Maintaining Level of an Embankment
417
Constructing a roadway embankment over uneven terrain requires precise leveling to ensure stability and proper drainage. Surveyors use a leveling instrument and staff to calculate ground elevations and determine the required fill material at each point along the embankment alignment.The process begins by positioning a leveling instrument near a benchmark with a known elevation. A backsight reading establishes the instrument height, which serves as a reference for subsequent measurements. A...
417
01:30Enzyme Inhibition
91.7K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.7K
01:27Ovarian Cycle
3.6K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
3.6K
01:25Role of Vitamins in Maintaining Bone Health
5.2K
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
5.2K
02:34Inhibition of Cdk Activity
5.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.6K